Literature DB >> 9447439

Functional disability in Alzheimer's disease.

S Gauthier1, I Gélinas, L Gauthier.   

Abstract

Functional impairment is a core symptom of Alzheimer's disease. The most accurate indicator of functional impairment is the decline in performance of Activities of Daily Living (ADL). Several scales have been used to measure ADL in geriatric and Alzheimer's disease (AD) populations including the Disability Assessment for Dementia (DAD). The key to making a correct differential diagnosis between benign cognitive impairment and dementia is the detection of a decline in functioning. The instrumental ADL (IADL) relevant items of the DAD could provide crucial guidance in the diagnosis of early stage AD for primary care physicians. It is anticipated that the role of primary care physicians, already essential for the management of the AD patient, will expand to include the diagnosis of earlier cases and the prescription of cholinergic drugs as treatment. ADL assessment tools such as the DAD may help their tasks.

Entities:  

Mesh:

Year:  1997        PMID: 9447439     DOI: 10.1017/s1041610297004857

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  27 in total

Review 1.  Functional Disability in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis.

Authors:  Cutter A Lindbergh; Rodney K Dishman; L Stephen Miller
Journal:  Neuropsychol Rev       Date:  2016-07-08       Impact factor: 7.444

2.  Mild Cognitive Impairment and Changes in Everyday Function Over Time: The Importance of Evaluating Both Speed and Accuracy.

Authors:  Caroline L Lassen-Greene; Kayla Steward; Ozioma Okonkwo; Ellen Porter; Michael Crowe; David E Vance; H Randall Griffith; Karlene Ball; Daniel C Marson; Virginia G Wadley
Journal:  J Geriatr Psychiatry Neurol       Date:  2017-07       Impact factor: 2.680

3.  Functional correlates of instrumental activities of daily living in mild Alzheimer's disease.

Authors:  Neelesh K Nadkarni; Naama Levy-Cooperman; Sandra E Black
Journal:  Neurobiol Aging       Date:  2010-03-31       Impact factor: 4.673

4.  Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.

Authors:  Joan Hq Shen; Qi Shen; Holly Yu; Jin-Shei Lai; Jennifer L Beaumont; Zhenxin Zhang; Huali Wang; Seong Yoon Kim; Christopher Chen; Timothy Kwok; Shuu-Jiun Wang; Dong Young Lee; John Harrison; Jeffrey Cummings
Journal:  Am J Neurodegener Dis       Date:  2014-12-05

5.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

6.  A community-based approach to trials of aerobic exercise in aging and Alzheimer's disease.

Authors:  Eric D Vidoni; Angela Van Sciver; David K Johnson; Jinghua He; Robyn Honea; Brian Haines; Jami Goodwin; M Pat Laubinger; Heather S Anderson; Patricia M Kluding; Joseph E Donnelly; Sandra A Billinger; Jeffrey M Burns
Journal:  Contemp Clin Trials       Date:  2012-08-07       Impact factor: 2.226

7.  Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression.

Authors:  Basil H Ridha; Valerie M Anderson; Josephine Barnes; Richard G Boyes; Shona L Price; Martin N Rossor; Jennifer L Whitwell; Lisa Jenkins; Ronald S Black; Micheal Grundman; Nick C Fox
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

Review 8.  Assessing and predicting functional impairment in Alzheimer's disease: the emerging role of frontal system dysfunction.

Authors:  Patricia A Boyle
Journal:  Curr Psychiatry Rep       Date:  2004-02       Impact factor: 5.285

9.  Towards a cognitive stimulation program using an errorless learning paradigm in amnestic mild cognitive impairment.

Authors:  Léonie Jean; Martine Simard; Robert van Reekum; Marie-Eve Bergeron
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

10.  Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.

Authors:  Bruno Vellas; R Black; Leon J Thal; Nick C Fox; M Daniels; G McLennan; C Tompkins; C Leibman; M Pomfret; Michael Grundman
Journal:  Curr Alzheimer Res       Date:  2009-04       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.